Specijalna Bolnica Medico

The trials here

What the 40 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis7 trials
• Lung cancer5 trials
• Crohn's disease4 trials
• Atopic dermatitis (eczema)3 trials
• IgA nephropathy3 trials
• Type 2 diabetes3 trials
• Antiphospholipid syndrome2 trials
• Chronic spontaneous urticaria2 trials
• Dermatomyositis and polymyositis (myositis)2 trials
• Heart failure2 trials
• Hidradenitis suppurativa2 trials
• Immune thrombocytopenia (ITP)2 trials
• and 8 more

Phase

• Phase 324 trials
• Phase 212 trials
• Phase 13 trials
• Phase 2/31 trial

Status

• Active, not recruiting12 trials
• Recruiting12 trials
• Completed9 trials
• Not yet recruiting5 trials
• Withdrawn2 trials

Lead sponsor

• AbbVie7 trials
• Boehringer Ingelheim3 trials
• Mirati Therapeutics Inc.3 trials
• Novo Nordisk A/S3 trials
• Sanofi-Aventis Recherche & Developpement2 trials
• and 22 more

Running trials

• Not yet recruiting

  A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both

  NCT07931599· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have completed previous zigakibart trials

  2024-519638-22-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT07711418· Phase 3· Nektar Therapeutics· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease

  2025-522001-38-00· Phase 2· Mirador Therapeutics Inc.· Source

• Recruiting

  Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria

  2025-522878-36-00· Phase 3· Celldex Therapeutics Inc.· Source

• Recruiting

  A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  NCT07409181· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

  NCT07047690· Phase 2· Galderma R&D· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  NCT06880744· Phase 3· AbbVie· Source

• Recruiting

  A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06935357· Phase 3· Biogen· Source

• Recruiting

  Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure

  NCT06929806· Phase 3· Pharmacosmos A/S· Source

• Recruiting

  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  NCT06875310· Phase 3· Mirati Therapeutics Inc.· Source

• Recruiting

  Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)

  2024-511346-39-00· Phase 1· Chugai Pharmaceutical Co. Ltd.· Source

• Recruiting

  An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis

  2023-507853-13-00· Phase 2· Eli Lilly & Co.· Source

• Recruiting

  Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  NCT06548542· Phase 2· AbbVie· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

  NCT06461897· Phase 3· AbbVie· Source

• Recruiting

  Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

  NCT06371417· Phase 1· Chugai Pharmaceutical· Source

• Active, not recruiting

  A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

  NCT06455202· Phase 3· Celldex Therapeutics· Source

• Recruiting

  A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  NCT06226883· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source

• Active, not recruiting

  A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06468228· Phase 3· AbbVie· Source

• Recruiting

  A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

  NCT06311682· Phase 3· LEO Pharma· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

  NCT06257875· Phase 2· AbbVie· Source

• Recruiting

  A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

  NCT06012240· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study of Zigakibart in Adults With IgA Nephropathy

  NCT05852938· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

  NCT05889182· Phase 3· AbbVie· Source

• Active, not recruiting

  HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.

  NCT05636176· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

  NCT05678673· Phase 3· Exelixis· Source

• Recruiting

  Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  NCT04613596· Phase 2/3· Mirati Therapeutics Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease2 recruiting
• IgA nephropathy2 recruiting
• Lung cancer2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Type 2 diabetes2 recruiting
• Ulcerative colitis2 recruiting
• Antiphospholipid syndrome1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Chronic spontaneous urticaria1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Lupus (SLE)1 recruiting

Closed trials

• Completed

  A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative colitis

  NCT07222189· Phase 2· Sanofi-Aventis Recherche & Developpement· Source

• Completed

  A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis.

  2023-507705-34-00· Phase 3· Alvotech Swiss AG· Source

• Completed

  A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease.

  NCT06637631· Phase 2· Sanofi-Aventis Recherche & Developpement· Source

• Active, not recruiting

  Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

  NCT06635824· Phase 3· Genmab· Source

• Recruiting

  A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma

  2023-510017-26-00· Phase 1· Celltrion Inc.· Source

• Active, not recruiting

  A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC

  2023-504753-12-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Completed

  Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis

  2023-508679-34-00· Phase 2· Anaptysbio Inc.· Source

• Active, not recruiting

  Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

  NCT05853575· Phase 2· Mirati Therapeutics Inc.· Source

• Withdrawn

  Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

  NCT06083675· Phase 3· Novo Nordisk A/S· Source

• Completed

  Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

  NCT05251259· Phase 2· AstraZeneca· Source

• Completed

  The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy

  NCT04636814· Phase 3· Chiesi Farmaceutici S.p.A.· Source